Skip to main content
Clinical Trials/NCT06059794
NCT06059794
Completed
Not Applicable

Assessment of Anxiety Disorder in Relation to PUQE Score of Nausea and Vomiting in First Trimester Pregnancy

Ain Shams Maternity Hospital1 site in 1 country102 target enrollmentJanuary 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Nausea Gravidarum
Sponsor
Ain Shams Maternity Hospital
Enrollment
102
Locations
1
Primary Endpoint
Generalised Anxiety Disorder Assessment (GAD-7)
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The goal of this observational study is to learn more about the relation between anxiety (assessed by GAD-7 questionnaire) and the nausea and vomiting in pregnancy (objectively measured by PUQE score).

Participants will answer 2 questionnaires: (GAD-7) for anxiety; and (PUQE score) for nausea and vomiting.

Detailed Description

Study Procedures: * Protocol approval will be sought from the ethical committee of the department of Obstetrics \& Gynecology, Faculty of Medicine, Ain Shams University. * Recruitment of pregnant women complaining of nausea and vomiting in pregnancy (NVP) in first trimester will be done from the outpatient clinic and antenatal ward in Ain Shams University Maternity Hospital. * An informed written consent will be taken from all participants before enrollment in the study. * History taking, examination, and investigations (CBC, ultrasound, acetone in urine, serum sodium, potassium, alanine transaminase (ALT), aspartate transaminase (AST), serum creatinine) will be done to identify eligible patients according to the inclusion and exclusion criteria. * PUQE score will be calculated for each patient. Patients will be classified into 3 groups (mild, moderate, severe) accordingly. * GAD-7 questionnaire will be calculated for each patient. Degree of anxiety will be classified into 4 groups (minimal, mild, moderate, severe) accordingly. * Data will be recorded in a case report form. * Statistical analysis will be done accordingly.

Registry
clinicaltrials.gov
Start Date
January 1, 2023
End Date
March 19, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Rania Hassan Mostafa

principal investigator

Ain Shams Maternity Hospital

Eligibility Criteria

Inclusion Criteria

  • Pregnant women in first trimester complaining of NVP
  • Age (18-40) years

Exclusion Criteria

  • History of known medical problem (e.g., endocrine abnormalities, gastrointestinal disease).
  • Known current or past psychiatric disorder (e.g., depression, anxiety, bipolar disorder, delirium, eating disorders, and psychotic disorder)
  • Multiple pregnancy
  • Known obstetric complications (non-viable pregnancy; either ectopic pregnancy; gestational trophoblastic disease, or miscarriage).
  • Medications (including antidepressant, anti-psychotic or other psychiatric drugs during the last 6 months) or illegal drug or narcotic use that would affect the test results
  • Current or past history of cognitive incompetence which can make it difficult to understand how to score GAD-7 questionnaire.

Outcomes

Primary Outcomes

Generalised Anxiety Disorder Assessment (GAD-7)

Time Frame: Baseline

The Generalised Anxiety Disorder Assessment (GAD-7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Response options include "not at all", "several days", "more than half the days" and "nearly every day"

Pregnancy-Unique Quantification of Emesis (PUQE) score

Time Frame: Baseline

The Pregnancy-Unique Quantification of Emesis (PUQE) is a scoring system to quantify the severity of nausea and vomiting of pregnancy, based on quantification of the 3 physical symptoms of (nausea, vomiting and retching).

Secondary Outcomes

  • Disturbance in Potassium(immediately after the intervention)
  • Disturbance in Sodium.(immediately after the intervention)
  • Dehydration(immediately after the intervention)
  • Ketonuria(immediately after the intervention)
  • Hospital admission(immediately after the intervention)
  • Hospital stay(immediately after the intervention)

Study Sites (1)

Loading locations...

Similar Trials